Ventilator-associated pneumonia among ICU patients in WHO Southeast Asian region: A systematic review

Sanjeev Kharel, Anil Bist, Shyam Kumar Mishra

1 Maharajgunj Medical Campus, Tribhuvan University Institute of Medicine, Kathmandu, Nepal, 2 Department of Microbiology, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal

☯ These authors contributed equally to this work.
* kharel_sanjeev@iom.edu.np

Abstract

Ventilator-associated pneumonia (VAP) is one of the most frequent ICU-acquired infections and a leading cause of death among patients in Intensive Care Unit (ICU). The South East Asian Region is a part of the world with limited health resources where infectious diseases are still underestimated. We aimed to review the literature in this part of the world to describe incidence, mortality and microbiological evidence of VAP and explore preventive and control strategies. We selected 24 peer-reviewed articles published from January 1, 2000 to September 1, 2020 from electronic databases and manual searching for observational studies among adult patients diagnosed with VAP expressed per thousand days admitted in ICU. The VAP rates ranged from 2.13 to 116 per thousand days, varying among different countries of this region. A significant rate of mortality was observed in 13 studies ranging from 16.2% to 74.1%. Gram negative organisms like Acinetobacter spp., Pseudomonas aeruginosa and Klebsiella pneumoniae and Gram-positive organisms like Staphylococcus aureus and Enterococcus species were frequently found. Our findings suggest an alarming situation of VAP among patients of most of the countries of this region with increasing incidence, mortality and antibiotic resistance. Thus, there is an urgent need for cost effective control and preventive measures like interventional studies and educational programs on staff training, hand hygiene, awareness on antibiotic resistance, implementation of antibiotic stewardship programs and appropriate use of ventilator bundle approach.

Introduction

Ventilator-associated pneumonia (VAP) is defined as pneumonia or infection in lung parenchyma acquired in patients after invasive mechanical ventilation after 48–72 hours. New or progressive infiltrates, systemic infection (fever, altered white blood cell counts), changes in sputum characteristics, and the detection of a causative agent are seen in VAP patients [1]. VAP is the most common ICU acquired pneumonia among mechanically ventilated patients [2]. VAP is recognized as a major issue worldwide, and common healthcare-associated infection(HAI) among developing countries associated with mortality, longer length of
stay, and associated cost burden among patients [3–5]. There is variability in the VAP rate in different studies caused by differing diagnostic criteria, ICUs type, patients’ characteristics, and also varying causative microorganisms associated with patients’ characteristics, length of stay, and antibiotic use in hospitals [6].

VAP risk factors include oropharyngeal and gastric colonization, thermal injuries; post-traumatic, postsurgical intervention factors such as emergency intubation, reintubation, tracheostomy, bronchoscopy and inserting nasogastric tube; patients’ body positioning, level of consciousness, stress ulcer prophylaxis, and use of medications, including sedative agents, immunosuppression and antibiotics [7,8]. There is still confusion in VAP’s epidemiology and diagnostic criteria, although of great advancement in microbiological tools and antimicrobials regimen for treatment. This has affected rapid diagnosis and treatment with suitable antibiotics deteriorating patient’s prognosis and increase in the number of new multi-drug resistant pathogens (MDR) [2,9].

HAI are still underestimated in resource-limited countries. Although the economics of low- and middle-income countries of Asia are rapidly developing but still there is gradual advancement in the health sector causing limited access to modern health facilities to increasing population. Improvement in infection-control practices and surveillance systems can improve the safety and reduce the occurrence of adverse events among patients [10,11]. Most countries in the South-East Asian Region according to World Health Organization (WHO SEAR) still have a high burden of infectious disease even after years of development and rise in the economy [12]. Although there are little studies on countries of WHO SEAR region on this critical issue of ICU, there is a lack of rigorously carried out analytical data and reviews in this region. The main objective of this research is to estimate the incidence, mortality, and etiological agents of VAP. This reliable and updated data would be help for assessing the gravity of the situation, providing evidence for patients, clinicians and policy makers for planning infection control and other prevention strategies along with interventional educational programs.

**Materials and methods**

**Search strategy**

We conducted an extensive literature search of the three electronic databases, namely PubMed, Embase, and Google Scholar, to identify all the peer-reviewed research articles published within the time frame of January 1 2000 to September 1 2020. The search strategy is given in S1 File. All the databases were searched using relevant MeSH Terms and Emtree terms in PubMed and Embase, respectively. The terms “Ventilator-associated Pneumonia”, “Bacterial Pneumonia”, “Microbiology”, “Mechanical ventilation” were searched under MeSH terms along with the names of different countries that belong to the WHO SEAR. All the references to the studies qualified for the review were also thoroughly searched for additional relevant articles. Our systematic review was not previously registered with PROSPERO or any of the international Systematic Review Registers.

**Eligibility criteria**

Studies published in English (observational studies: surveillance, retrospective, and prospective studies) including information on at least prevalence or incidence or incidence rate of Ventilator associated pneumonia among adults expressed as episodes per 1000 ventilator days were considered eligible for inclusion. Besides, studies conducted in the WHO SEAR region examining mechanically ventilated adults in ICU were included.
The following exclusion criteria were included:

- Review articles, research protocols
- Case series/case reports
- Symposium/conference proceedings, commentaries/editorials/letters, views/opinions
- Studies with unclear study designs and unavailable data for risk calculation.
- Full text unavailable,
- Not in English

For two or more studies, including the same set of patients, we included the study with a more significant number of patients. The PRISMA diagram detailing the identification and selection process is given in Fig 1.

Data extraction and management

According to prespecified inclusion and exclusion criteria, two independent authors (SK and AB) screened the articles remaining after duplicates removal. Full-text articles were retrieved, and studies were shortlisted to be included in the review, which met the eligibility criteria. For full text and missing data, authors of respective studies were contacted via email and ResearchGate. The disparities and confusions among two authors were resolved by consultation of a third author (SKM). The data was extracted using the data abstraction Spreadsheet in Microsoft Excel version 2013 (Microsoft Corp., Redmond, WA, USA) under the following variables: Name of the Author, Country where the study was done, Year of the Publication, Type of Study, Type of the ICU, Criteria used for diagnosis of Ventilator-Associated pneumonia (VAP), Incidence of VAP, the Mortality rate in the VAP patients and microbiological profile.

Results

Study selection

A total of 367 articles were obtained after a thorough search through the databases. After adjusting all the duplicate articles, a total of 303 articles remained for further processing. After the title and abstract screening, 236 of those papers were omitted because they did not follow the inclusion requirements. The full text was obtained for the remaining 67 articles. Of the 67 full-text posts, 43 were rejected because the findings of interest were not found. Finally, 24 articles were included in the review.

Study characteristics

Altogether 24 studies (prospective, retrospective, and surveillance study) conducted in hospital settings among different adult patients presented in ICU were reviewed qualitatively. Studies included US Centers for Disease Control and Prevention (CDC) and Clinical Pulmonary Infection Score (CPIS) as diagnostic criteria for VAP expressed per thousand ventilator days. Countries of WHO SEAR (Bangladesh, India, South Korea, Nepal and Thailand) were study settings for the study. While patients of five countries of WHO SEAR (Myanmar, Maldives, Timor-Leste, Bhutan, Indonesia, and Sri Lanka) with no data on VAP were not included in the review. A detailed description of the characteristics of individual studies is provided in Table 1.
**Outcome**

**Ventilator-associated pneumonia incidence rate.** The VAP incidence rate ranged from 2.13 per thousand ventilator days to 116 per thousand ventilator days differing greatly between countries. The highest VAP prevalence rate was reported from the Medical Intensive Care Unit (MICU), India, whereas the lowest was from the Palliative Care ICU setting, South Korea. The VAP rate reported from various studies are reported in Table 1.

**Mortality.** Thirteen of the 24 articles included in the review reported the mortality rate in VAP patients. The mortality rate ranged from 16.2% to 74.17%. The highest mortality rate was reported from a study of India. No mortality rates were reported from studies of Thailand and Korea. The detailed description of the mortality rate reported from studies of different countries is shown in Table 1.
Microbiology of VAP. Twenty-four studies included data on microbiology, causing VAP, as shown in Table 2. Gram-negative organisms caused the majority of VAP episodes, followed by Gram-positive organisms. Only a few studies isolated other species like fungi causing VAP episodes.

Comparison among microbiology of VAP of 24 studies (Table 2) showed Acinetobacter sp., followed by Pseudomonas aeruginosa and then Klebsiella pneumoniae as common Gram-negative organisms causing VAP while Staphylococcus aureus and Enterococcus species as common Gram-positive organisms. Some studies also isolated sensitive and resistant forms of Gram-positive bacteria like MSSA (Methicillin Sensitive Staphylococcus Aureus), MRSA
| Study            | Year | Acinetobacter spp. | Klebsiella pneumoniae | Escherichia coli | Pseudomonas aeruginosa | Burkholderia cepacia | Enterobacter sp. | Staphylococcus aureus | MRSA | Enteroceccus spp. | MSSA | Candida spp. |
|------------------|------|---------------------|-----------------------|------------------|------------------------|----------------------|-------------------|----------------------|------|-------------------|------|-------------|
| Chittawatanarat et al. [13] | 2014 | 38.70%              | 17.30%                | 4%               | 16.70%                 | -                    | 4.70%             | 4%                   | 0.70% | 7.70%             |      |             |
| Dasgupta et al. [14] | 2015 | -                   | 15.40%                | 15.40%           | 45.50%                 | -                    | -                 | -                    | 7.70% | -                 |      |             |
| Datta et al. [15] | 2014 | 41.30%              | 15.20%                | 34.70%           | -                      | -                    | -                 | -                    | 6.50% | -                 |      |             |
| Joseph et al. [16] | 2009 | 21.30%              | -                     | 21.30%           | -                      | 14.90%              | -                 | -                    | -     | -                 |      |             |
| Khan et al. [17] | 2016 | 18                  | 12                    | 4                 | 18                     | 2                    | -                 | -                    | -     | -                 |      |             |
| Khurana et al. [18] | 2017 | 54%                 | 13%                   | 3%                | 21%                    | 1%                   | -                 | 3%                   | 0.70% | -                 |      |             |
| Kumar et al. [19] | 2017 | 40%                 | -                     | -                 | -                      | -                    | -                 | -                    | -     | -                 |      |             |
| Mallick et al. [20] | 2015 | 52%                 | 16%                   | 8%                | 32%                    | -                    | -                 | 8%                   | -     | -                 |      |             |
| Maqbool et al. [21] | 2017 | -                   | -                     | -                 | -                      | -                    | -                 | -                    | -     | -                 |      |             |
| Masih et al. [22] | 2016 | 20                  | 22%                   | -                 | 30%                    | -                    | -                 | 26%                   | 3%    | -                 |      |             |
| Mathai et al. [23] | 2016 | 53.20%              | 15.60%                | 8.25%            | 12.80%                 | -                    | -                 | 3.60%                 | 0.90% | 5%                |      |             |
| Mathur et al. [24] | 2015 | 54%                 | 13%                   | 3%                | 21%                    | 1%                   | -                 | 3%                   | -     | -                 |      |             |
| Mukhopadhyya et al. [25] | 2010 | 76%                 | 14%                   | 14%               | 43%                    | -                    | -                 | 9%                   | -     | -                 |      |             |
| Nakaviroj et al. [26] | 2014 | 66.60%              | -                     | 4.80%            | 19.04%                 | -                    | -                 | -                    | 9.50% | -                 |      |             |
| Panjali et al. [27] | 2017 | 43%                 | 25%                   | 13.80%           | 8.30%                  | 6.9 0%               | -                 | -                    | -     | -                 |      |             |
| Park et al. [28] | 2014 | 15.40%              | -                     | -                 | 30.80%                 | -                    | -                 | 30.80%                | -     | 3%                |      |             |
| Rakshit et al. [29] | 2005 | 8%                  | 29%                   | 13%               | 46%                    | -                    | -                 | 25%                  | -     | -                 |      |             |
| Ranjan et al. [30] | 2014 | 32.86%              | 21.43%                | 1.43%            | 25.71%                 | 4.28%               | 2.85%             | 1.43%                | -     | -                 |      |             |
| Recchaipisit et al. [31] | 2013 | 26.9%/38.9%        | 15.4%/12.3%           | 4.8%/2.9%        | 25%/22%                | -                   | 8.8%/6.3%        | 7.2%/6%               | 0.80% | -                 |      |             |
| Rit et al. [32] | 2014 | 17.60%              | -                     | -                 | 30.70%                 | -                    | 35.20%           | -                    | 7.60% | 11.70%            |      |             |
| Sachdev et al. [33] | 2017 | 32%                 | 24%                   | -                 | 26.66%                 | -                    | -                 | 2                    | -     | -                 |      |             |
| Singh et al. [34] | 2010 | -                   | -                     | -                 | -                      | -                    | -                 | -                    | -     | -                 |      |             |
| Singh et al. [35] | 2013 | -                   | -                     | -                 | -                      | -                    | -                 | -                    | -     | -                 |      |             |
| Thongpiyapoom et al. [36] | 2004 | 5                   | 2                     | -                 | 4                      | -                    | 1                 | 1                    | -     | -                 |      |             |

Note: MRSA = Methicillin Resistant Staphylococcus Aureus. MSSA = Methicillin Sensitive Staphylococcus Aureus.
* = Studies that have listed the micro-organisms but frequency is not given.
** = Study with data of two years 2008/2009.
*** = Studies in which frequency of micro-organism isolated is given in numbers.
(Methicillin Resistant Staphylococcus Aureus) and VRE (Vancomycin Resistant Enterococci). Candida albicans was the most common fungal isolate described in only seven studies.

**Discussion**

Our review highlights the situation of VAP among the populations of countries of WHO SEAR. We found a wide range with much variability in the VAP rate, ranging from 2.13 to 166 per thousand ventilator days among these countries, showing most studies with alarming VAP situations. High mortality rates were reported in various studies and majority of the VAP episodes were caused by Gram-negative organisms, followed by Gram-positive organisms.

Differences in advancement and availability of health facilities, economic status, study setting (Medical or Surgical ICU) [37], criteria to diagnose VAP, patient characteristics diagnosed with various diseases, and medical staff practices in different regions of SEAR may be the most probable cause for variability in VAP rate.

A review by Arabi et al. among adults in developing countries showed incidence rates ranging from 10 to 41.7 per 1000 ventilator-days [38]. While Bonnel et al. estimated the VAP incidence in twenty-two Asian countries, including China, and showed a lower VAP incidence in high-income countries than lower-income countries (9 vs. 18.5 per 1,000 ventilator-days respectively) [39]. Studies from different parts of Asia (Qatar, Lebanon, Arabian Gulf countries, Iran, Japan) also showed a varied incidence rate from 4.8 to 12.6 per thousand [40–44]. Ding et al. also showed an incidence rate of 22.83 patients per 1000 ventilator days in China’s mainland [45].

Some of the studies in our review have a similar incidence rate of VAP as of the above studies, but the remaining studies have a higher incidence. Various studies of Asia found out trauma, steroid use, enteral feeding, nasogastric tube placement, tracheostomy, reintubation, central venous catheter, blood transfusion, and COPD as risk factors for high VAP [46,47]. Similarly, globally found risk factors were aging males, increased ventilation time, consciousness disorders like swallowing, coughing; complications of burns, chronic disease, long time prophylactic use of antibiotics, and gene polymorphisms along with smoking [48]. Controlling these risk factors among patients can reduce incidence and mortality of VAP.

We found the highest incidence rate among ICU admitted patients of an Indian hospital [25], while the lowest was found in a South Korean hospital [28]. Possible reasons for the high rate may be due a smaller number of patients and study duration, and more male to female ratio. A review article found the male gender as a potential risk factor for VAP [48]. The study in a South Korean hospital equipped with advanced health care facilities showed the least VAP rate among cancer patients using antibiotics, antacid, along with health care staffs using a ventilator bundle approach [28].

We found a variable rate of VAP among different ICUs. Different infection control practices, injured and trauma patients with increased risk and medical staff’s practices are probable reasons [49–51]. There is a lack of an acceptable gold standard for diagnosing VAP. Because of high sensitivity, the diagnostic modality of CPIS criteria is accepted widely. An application of this diagnostic modality is cost-effective and useful in a low resource setting like most SEAR countries [52,53].

Our study showed mortality rate ranged from 16.2% to 74.17%. The highest mortality rate was reported from among Indian patients [33]. We found that surgical ICU has more mortality than the medical ICU but cannot be generalized. This rate is similar to a study among developing countries by Arabi et al. In the USA mortality rate was reported by the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) as 13%, and in Europe 30-day mortality rate was 29.9% [54,55] less than the countries of WHO SEAR. High
mortality in many areas in our study settings is due to lack of medical advancements in health care, lack of specialized ICU unit, and cost burden of personal and high antibiotic resistance [39].

Data on microbiology is similar to Arabi et al. showing Gram-negative bacilli as the most common pathogen (41–92%), followed by Gram-positive cocci (6–58%) [38]. An analysis done in Egypt also showed that similar common causative organisms; Pseudomonas aeruginosa, Klebsiella, Escherichia coli, Staphylococcus Aureus, Acinetobacter spp., Candida spp., and Proteus spp. were the most common microorganisms isolated while other organisms isolated were MRSA, Streptococci, Polymicrobial, Coagulase negative Staphylococci (CoNS), VRSA and MSSA [56].

As most WHO SEAR countries are low and middle income with a high VAP rate, a cost-effective educational intervention program is needed to reduce VAP. Use of heat and moisture exchanger (HME) vs. heated humidifying system (HHS), Staff education program, Hand hygiene training, and feedback program, awareness program and training on proper handling of respiratory secretions of critical ICU patients [57–59] are some of the cost-effective measures applied in these countries. Also, a ventricular bundle approach (head of bed elevation, peptic ulcer disease prophylaxis, deep venous thrombosis prophylaxis, and oral decontamination with chlorhexidine 0.12%) can be adopted for reducing VAP incidence [60]. Antibiotics are chosen by physicians, according to the knowledge of local microbiology causing VAP and their susceptibility patterns [61]. To keep in check the increasing drug resistant organisms with limited antibiotic inventory, infection control and antibiotic stewardship programs are mainstay strategies being adopted [62,63]. Thus, this review will motivate more surveillance and intervention studies to find risk factors and preventive strategies for VAP in countries of SEAR, as most countries do not have data on VAP. The outcomes chosen in our review provides a suitable overview to address the magnitude and scope of problem of VAP that helps us to know either our progress towards solving problems of VAP or the enough resources, manpower and economy to control and prevent infection or reduce the antibiotic resistance.

**Strengths and limitations**

The major strength of our study is that this is the first systematic review conducted in this part of world exploring a major problem needed to be addressed. Our study has several shortcomings. Our study covered data of only five countries in this region which is the main limitation of our study. Another limitation was exclusion of non-English articles. While, we have also not described about outcomes such as early onset VAP and late onset VAP. Lastly, articles reporting incidence of ventilator associated Pneumonia parameters other than per thousand ventilator days were not included.

**Conclusion**

Our review found a variable incidence of VAP in WHO SEAR regions, a comparatively alarming situation in most of these region’s resource-limited countries with increasing mortality. As VAP is a critical issue in ICU with a high-cost burden with emerging antibiotic resistance, various interventional educational programs like staff training, hygiene awareness; use of ventilator bundle approach and surveillance programs along with addressing the possible risk factors warrants active participation from physicians, health workers to hospital administration and policymakers. Similarly, accurate and comprehensive testing of antimicrobial susceptibility and continuous monitoring along with implementation of antibiotic stewardship can possibly reduce the future risk of VAP in this region.
Supporting information

S1 Table. PRISMA checklist for systematic review and meta-analysis. (PDF)

S1 File. Search strategy of PUBMED and EMBASE. (PDF)

Acknowledgments

We want to acknowledge Dr. Ravi Pradhan and Dr. Siddhartha Bhandari for proofreading the manuscript.

Author Contributions

Conceptualization: Sanjeev Kharel, Anil Bist.
Methodology: Sanjeev Kharel, Anil Bist.
Resources: Sanjeev Kharel.
Supervision: Shyam Kumar Mishra.
Validation: Shyam Kumar Mishra.
Writing – original draft: Sanjeev Kharel, Anil Bist.
Writing – review & editing: Sanjeev Kharel, Shyam Kumar Mishra.

References

1. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005 Feb 15; 171(4):388–416. https://doi.org/10.1164/rccm.200405-644ST PMID: 15699079

2. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, et al. Health Care–Associated Infections. Vol. 173, JAMA Internal Medicine. 2013. p. 2039. Available from: https://doi.org/10.1001/jamainternmed.2013.9763 PMID: 23999949

3. Kollef MH, Chastre J, Fagon J-Y, François B, Niederman MS, Rello J, et al. Global Prospective Epidemiologic and Surveillance Study of Ventilator-Associated Pneumonia due to Pseudomonas aeruginosa*. Vol. 42, Critical Care Medicine. 2014. p. 2178–87. Available from: https://doi.org/10.1097/CCM.0000000000000510 PMID: 25054674

4. Barbier F, Andremont A, Wolff M, Boudadma L. Hospital-acquired pneumonia and ventilator-associated pneumonia. Vol. 19, Current Opinion in Pulmonary Medicine. 2013. p. 216–28. Available from: https://doi.org/10.1097/MCP.0b013e32835f27be PMID: 23524477

5. Allegranzi B, Nejad SB, Combes C, Graafmans W, Attar H, Donaldson L, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Vol. 377, The Lancet. 2011. p. 228–41. Available from: https://doi.org/10.1016/S0140-6736(10)61458-4 PMID: 21146207

6. Alp E, Voss A. Annals of Clinical Microbiology and Antimicrobials. Vol. 5. 2006. p. 7. Available from: https://doi.org/10.1186/1476-0711-5-7 PMID: 16600048

7. Augustyn B. Ventilator-Associated Pneumonia. Vol. 27, Critical Care Nurse. 2007. p. 32–9. Available from: http://dx.doi.org/10.4037/ccn2007.27.4.32. PMID: 17671243

8. Villar CC, Pannuti CM, Nery DM, Morillo CMR, Carmona MJC, Romito GA. Effectiveness of Intraoral Chlorhexidine Protocols in the Prevention of Ventilator-Associated Pneumonia: Meta-Analysis and Systematic Review. Respir Care. 2016 Sep; 61(9):1245–59. https://doi.org/10.4187/respcare.04610 PMID: 27507174

9. Jakribettu R, Boloor R. Characterisation of aerobic bacteria isolated from endotracheal aspirate in adult patients suspected ventilator associated pneumonia in a tertiary care center in Mangalore. Vol. 6, Saudi Journal of Anaesthesia. 2012. p. 115. Available from: https://doi.org/10.4103/1658-354X.97022 PMID: 22754435
10. Becerra MR, Tantaleán JA, Suárez VJ, Alvarado MC, Candela JL, Urcía FC. Epidemiologic surveillance of nosocomial infections in a Pediatric Intensive Care Unit of a developing country. Vol. 10, BMC Pediatrics. 2010. Available from: http://dx.doi.org/10.1186/1471-2431-10-66.

11. Available from: International Finance Corporation, World Bank Group. Healthcare market assessment: East Asia 2016. Available at: https://openknowledge.worldbank.org/handle/10986/26319.

12. Gupta I, Guin P. Communicable diseases in the South-East Asia Region of the World Health Organization: towards a more effective response. Bull World Health Organ. 2010 Mar; 88(3):199–205. https://doi.org/10.2471/BLT.09.065540 Erratum in: Bull World Health Organ. 2010 Apr 1;88(4):320. PMID: 20428387; PMCID: PMC2828785.

13. Chittawataranarat K, Jaipakdee W, Chotirosrimit N, Chandachak M, Jirapongcharoenlap T. Microbiology, resistance patterns, and risk factors of mortality in ventilator-associated bacterial pneumonia in a Northern Thai tertiary-care university based general surgical intensive care unit. Infection and Drug Resistance. 2014. p. 203. Available from: https://doi.org/10.2147/IDR.S67267 PMID: 25152627

14. Hazra A, Dasgupta S, Das S, Chawan NS. Nosocomial infections in the intensive care unit: Incidence, risk factors, outcome and associated pathogens in a public tertiary teaching hospital of Eastern India. Vol. 19, Indian Journal of Critical Care Medicine. 2015. p. 14–20. Available from: https://doi.org/10.4103/0972-5229.148633 PMID: 25624645

15. Datta P, Rani H, Chauhan R, Gombar S, Chander J. Health-care-associated infections: Risk factors and epidemiology from an intensive care unit in Northern India. Indian J Anaesth. 2014 Jan; 58(1):30–5. https://doi.org/10.4103/0019-5049.126785 PMID: 24700986

16. Joseph NM, Sista S, Dutta TK, Badhe AS, Parija SC. Ventilator-associated pneumonia in a tertiary care centre in India: incidence and risk factors. Vol. 3, The Journal of Infection in Developing Countries. 2009. p. 771–7. Available from: https://doi.org/10.3855/jidc.396 PMID: 20092978

17. Khan ID, Basu A, Kiran S, Trivedi S, Pandit P, Chattoraj A. Device-Associated Healthcare-Associated Infections (DA-HAI) and the caveat of multiresistance in a multidisciplinary intensive care unit. Vol. 73, Medical Journal Armed Forces India. 2017. p. 222–31. Available from: http://dx.doi.org/10.1016/j.mjafi.2016.10.008.

18. Mathur P, Khurana S, Kumar S, Soni K, Aggrawal R, Batra P, et al. Incidence of ventilator-associated pneumonia and impact of multidrug-resistant infections on patient’s outcome. Experience at an apex trauma centre in North India. Vol. 35, Indian Journal of Medical Microbiology. 2017. p. 504. Available from: https://doi.org/10.4103/ijmm.IJMM_16_186 PMID: 29405141

19. Kumar S, Sen P, Gaind R, Verma PK, Gupta P, Suri PR, et al. Prospective surveillance of device-associated health care-associated infection in an intensive care unit of a tertiary care hospital in New Delhi, India. Vol. 46, American Journal of Infection Control. 2018. p. 202–6. Available from: https://doi.org/10.1016/j.ajic.2017.08.037 PMID: 29046215

20. Mallick UK, Faruq MO, Ahsan AA, Fatema K, Ahmed F, Asaduzzaman M, et al. Spectrum of Early Onset and Late Onset Ventilator Associated Pneumonia(VAP) in a Tertiary Care Hospital of Bangladesh: A Prospective Cohort Study. Vol. 3, Bangladesh Critical Care Journal. 2015. p. 9–13. Available from: http://dx.doi.org/10.3329/bccj.v3i1.24095.

21. Maqbool M, Shabir A, Naqash H, Amin A, Koul RK, Shah P. Ventilator associated pneumonia—incidence and outcome in adults in medical intensive care unit of a tertiary care hospital of North India. Int J Sci Study. 2017, 4(10):73–76 (PDF).

22. Masih S, Goel S, Singh A, Tank R, Khichi S, Singh S. Incidence and risk factors associated with development of ventilator-associated pneumonia from a tertiary care center of northern India. International Journal of Research in Medical Sciences. 2016. p. 1692–7. Available from: https://doi.org/10.18203/2320-6012.ijrms20161251.

23. Mathai A, Phillips A, Isaac R. Ventilator-associated pneumonia: A persistent healthcare problem in Indian Intensive Care Units!. Vol. 33, Lung India. 2016. p. 512. Available from: https://doi.org/10.4103/0970-2113.188971 PMID: 27625445

24. Mathur P, Tak V, Gunjial J, Nair SA, Lalwani S, Kumar S, et al. Device-associated infections at a level-1 trauma centre of a developing Nation: Impact of automated surveillance, training and feedbacks. Vol. 33, Indian Journal of Medical Microbiology. 2015. p. 51. Available from: https://doi.org/10.4103/0255-0857.148378 PMID: 25560002

25. Mukhopadhyay C, Krishna S, Shenoy A, Prakashini K. Clinical, radiological and microbiological corroboration to assess the role of endotracheal aspirate in diagnosing ventilator-associated pneumonia in an intensive care unit of a tertiary care hospital, India. Vol. 14, International Journal of Infectious Diseases. 2010. p. e248. Available from: http://dx.doi.org/10.1016/j.ijid.2010.02.2040.

26. Nakaviroj S, Cherdruangsri R, Chaivat O. Incidence and risk factors for ventilator-associated pneumonia in the surgical intensive care unit, Siriraj Hospital. J Med Assoc Thai. 2014 Jan; 97 Suppl 1:S61–8. PMID: 24855844
27. Parajuli NP, Acharya SP, Dahal S, Singh JP, Mishra SK, Kattel HP, et al. Epidemiology of device-associated infections in an intensive care unit of a teaching hospital in Nepal: A prospective surveillance study from a developing country. Vol. 45, American Journal of Infection Control. 2017. p. 1024–9. Available from: https://doi.org/10.1016/j.ajic.2017.02.040 PMID: 28431848

28. Park S-A, Cho SS, Kwak GJ. Factors Influencing Ventilator-Associated Pneumonia in Cancer Patients. Vol. 15, Asian Pacific Journal of Cancer Prevention. 2014. p. 5787–91. Available from: https://doi.org/10.7314/apjcp.2014.15.4.5787 PMID: 25081653

29. Rakshit P, Nagar VS, Deshpande AK. Incidence, clinical outcome, and risk stratification of ventilator-associated pneumonia-a prospective cohort study. Vol. 9, Indian Journal of Critical Care Medicine. 2005. p. 211–6. Available from: http://dx.doi.org/10.4103/0972-5229.19761.

30. Chaudhry D, Chaudhary U, Ranjan N, Ranjan KP. Ventilator-associated pneumonia in a tertiary care intensive care unit: Analysis of incidence, risk factors and mortality. Vol. 18, Indian Journal of Critical Care Medicine. 2014. p. 200–4. Available from: https://doi.org/10.4103/0972-5229.130570 PMID: 24872648

31. Reechaipichitkul W, Phondongnok S, Bourporenn J, Chaimane P. Causative agents and resistance among hospital-acquired and ventilator-associated pneumonia patients at Sriragarind Hospital, northeastern Thailand. Southeast Asian J Trop Med Public Health. 2013 May; 44(3):490–502. PMID: 24050082

32. Rit K, Saha R, Chakraborty B, Majumder U. Ventilator associated pneumonia in a tertiary care hospital in India: Incidence, etiology, risk factors, role of multidrug resistant pathogens. Vol. 4, International Journal of Medicine and Public Health. 2014. p. 51. Available from: http://dx.doi.org/10.4103/2250-8598.127125.

33. Sachdeva D, Singh D, Loomba P, Kaur A, Tandon M, Bishnoi I. Assessment of surgical risk factors in the development of ventilator-associated pneumonia in neurosurgical intensive care unit patients: Alarming observations. Neurol India. 2017 Jul; 65(4):779–84. https://doi.org/10.4103/neuroindia.NI_814_16 PMID: 28681751

34. Singh S, Pandya Y, Patel R, Paliwal M, Wilson A, Trivedi S. Surveillance of device-associated infections at a teaching hospital in rural Gujarat—India. Vol. 28, Indian Journal of Medical Microbiology. 2010. p. 342. Available from: https://doi.org/10.4103/0255-0857.80514 PMID: 20966566

35. Singh S, Chaturvedi R, Garg SM, Datta R, Kumar A. Incidence of healthcare associated infection in the surgical ICU of a tertiary care hospital [Internet]. Vol. 69, Medical Journal Armed Forces India. 2013. p. 124–9. Available from: https://doi.org/10.1016/j.mjafi.2012.08.028 PMID: 24600084

36. Thongpiyapoom S, Narong MN, Suwalak N, Jamulitrat S, Intaraksa P, Boonrat J, et al. Device-associated infections and patterns of antimicrobial resistance in a medical-surgical intensive care unit in a university hospital in Thailand. J Med Assoc Thai. 2004 Jul; 87(7):819–24. PMID: 15521239

37. Raza M. W., Kazi B. M., Mustafa M., and Gould F. K. 2004. “Developing Countries Have Their Own Characteristic Problems with Infection Control.” The Journal of Hospital Infection 57 (4): 294–99. DOI: 10.1016/S0195-6701(03)00345-3

38. Arabi Y, Al-Shirawi N, Memish Z, Anzueto A. Ventilator-associated pneumonia in adults in developing countries: a systematic review. Int J Infect Dis. 2008 Sep; 12(5):505–12. https://doi.org/10.1016/j.ijid.2008.02.010 PMID: 18502674

39. Bonell A, Azarraty R, Huong VTL, Viet TL, Phu VD, Dat VQ, et al. A Systematic Review and Meta-analysis of Ventilator-associated Pneumonia in Adults in Asia: An Analysis of National Income Level on Incidence and Etiology. Clin Infect Dis. 2019 Jan 18; 68(3):511–8. https://doi.org/10.1093/cid/ciy543 PMID: 29982303

40. Ali HS, Khan FY, George S, Shaikh N, Al-Ajmi J. Epidemiology and Outcome of Ventilator-Associated Pneumonia in a Heterogeneous ICU Population in Qatar. Vol. 2016, BioMed Research International. 2016. p. 1–8. Available from: http://dx.doi.org/10.1155/2016/8231787.

41. Kanafani ZA, El Zakhem A, Zahreddine N, Ahmadieh R, Kanji SS. Ten-year surveillance study of ventilator-associated pneumonia at a tertiary care center in Lebanon. Vol. 12, Journal of Infection and Public Health. 2019. p. 492–5. Available from: https://doi.org/10.1016/j.jiph.2019.01.057 PMID: 30737129

42. El-Saed A, Al-Jardani A, Althaqafi A, Alansari H, Almaskari Z, et al. Ventilator-associated pneumonia rates in critical care units in 3 Arabian Gulf countries: A 6-year surveillance study. Am J Infect Control. 2016 Jul 1; 44(7):794–8. https://doi.org/10.1016/j.ajic.2016.01.042 PMID: 27040565

43. Athmani S, Hadadi A, Khorami E, Seifi A, Esmaeilpour Bazaz N. Ventilator-associated pneumonia in a teaching hospital in Tehran and use of the Iranian Nosocomial Infections Surveillance software. Vol. 19, Eastern Mediterranean Health Journal. 2013. p. 883–7. Available from: http://dx.doi.org/10.26719/2013.19.10.883 PMID: 24313153
44. Suka M, Yoshida K, Uno H, Takezawa J. Incidence and outcomes of ventilator-associated pneumonia in Japanese intensive care units: the Japanese nosocomial infection surveillance system. Infect Control Hosp Epidemiol. 2007 Mar; 28(3):307–13. https://doi.org/10.1086/511997 PMID: 17326021

45. Ding C, Zhang Y, Yang Z, Wang J, Jin A, Wang W, et al. Incidence, temporal trend and factors associated with ventilator-associated pneumonia in mainland China: a systematic review and meta-analysis. Vol. 17, BMC Infectious Diseases. 2017. Available from: https://doi.org/10.1186/s12879-017-2566-7 PMID: 28676087

46. Wang H, Yi M, Jia Y, Li Y, Bai C, Jiang D, et al. Incidence Rates, Risk Factors, and Mortality Rates of Ventilator-Associated Pneumonia: A metaanalysis. Available from: http://dx.doi.org/10.21203/rs.2.20681/v2.

47. Wałaszek M, Kosiarska A, Gniadek A, Kolpa M, Wolak Z, Dobroś W, et al. The risk factors for hospital-acquired pneumonia in the Intensive Care Unit. Przegl Epidemiol. 2016; 70(1):15–20, 107–10. PMID: 27344468

48. Wu D, Wu C, Zhang S, Zhong Y. Risk Factors of Ventilator-Associated Pneumonia in Critically Ill Patients. Front Pharmacol. 2019 May 9; 10:482. https://doi.org/10.3389/fphar.2019.00482 PMID: 31143118

49. Raza MW, Kazi BM, Mustafa M, Gould FK. Developing countries have their own characteristic problems with infection control. Vol. 57, Journal of Hospital Infection. 2004. p. 294–9. Available from: https://doi.org/10.1016/j.jhin.2004.03.019 PMID: 15262389

50. Chastre J, Fagon J-Y. Ventilator-associated Pneumonia. Vol. 165, American Journal of Respiratory and Critical Care Medicine. 2002. p. 867–903. Available from: https://doi.org/10.1164/ajrccm.165.7.2105078 PMID: 11934711

51. Cunnion KM, Weber DJ, Broadhead WE, Hanson LC, Pieper CF, Rutala WA. Risk factors for nosocomial pneumonia: comparing adult critical-care populations. Vol. 153, American Journal of Respiratory and Critical Care Medicine. 1996. p. 158–62. Available from: https://doi.org/10.1016/j.ajrccm.153.1.8542110 PMID: 8542110

52. Baker AM, Bowton DL, Haponik EF. Decision making in nosocomial pneumonia. An analytic approach to the interpretation of quantitative bronchosopic cultures. Chest. 1995 Jan; 107(1):85–95. https://doi.org/10.1378/chest.107.1.85 PMID: 7813319

53. Mishra DR, Shah N, Shah DS. Incidence and Outcome of Ventilator Associated Pneumonia in ICU of a Tertiary Care Hospital in Nepal. Vol. 56, Journal of Nepal Medical Association. 2017. p. 304–8. Available from: http://dx.doi.org/10.31729/jnma.3216. PMID: 29255310

54. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Vol. 63, Clinical Infectious Diseases. 2016. p. e61–111. Available from: https://doi.org/10.1093/cid/ciw353 PMID: 27418577

55. Martin-Löeches I, Rodriguez AH, Torres A. New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia: USA vs. Europe. Curr Opin Crit Care. 2018 Oct; 24(5):347–52. https://doi.org/10.1097/MCC.0000000000000535 PMID: 30063491

56. Fathy A, Abdelhafeez R, EL-Gilany A-H, Elhafez SAA. Analysis of ventilator associated pneumonia (VAP) studies in Egyptian University Hospitals. Vol. 62, Egyptian Journal of Chest Diseases and Tuberculosis. 2013. p. 17–25. Available from: http://dx.doi.org/10.1016/j.egcj.2013.04.008.

57. Memish ZA, Oni GA, Djazmati W, Cunningham G, Mah MW. A randomized clinical trial to compare the effects of a heat and moisture exchanger with a heated humidifying system on the occurrence rate of ventilator-associated pneumonia. Am J Infect Control. 2001 Oct; 29(5):301–5. https://doi.org/10.1016/S0196-6553(01)00090-9.

58. Salahuddin N, Zafar A, Sukhyani L, Rahim S, Noor MF, Hussain K, et al. Reducing ventilator-associated pneumonia rates through a staff education programme. J Hosp Infect. 2004 Jul; 57(3):223–7. https://doi.org/10.1016/S0195-6701(04)00059-7.

59. Baravbar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med. 2014 Jan; 189(1):14–20. https://doi.org/10.1164/rccm.201306-1020OC.
62. Chaudhry D, Prajapat B. Intensive care unit bugs in India: How do they differ from the Western world?. Vol. 5, The Journal of Association of Chest Physicians. 2017. p. 10. Available from: http://dx.doi.org/10.4103/2320-8775.196645.

63. Lee C-R, Cho I, Jeong B, Lee S. Strategies to Minimize Antibiotic Resistance. Vol. 10, International Journal of Environmental Research and Public Health. 2013. p. 4274–305. Available from: https://doi.org/10.3390/ijerph10094274 PMID: 24036486